Trial List
List all clinical trials by discovery date. Accepts regular expressions in search.
GET /trials/
{ "count": 728, "next": "http://api.gregory-ms.com/trials/?page=2", "previous": null, "results": [ { "trial_id": 391648, "title": "The Effect of Transcranial Direct Current Stimulation on Fatigue Among Multiple Sclerosis Patients.Patients", "summary": "<b>Condition</b>: Multiple Sclerosis<br /><b>Intervention</b>: Device: a-tDCS<br /><b>Sponsor</b>: Assiut University<br /><b>Not yet recruiting</b>", "published_date": "2022-09-29T12:00:00Z", "discovery_date": "2022-09-29T12:35:19.146318Z", "link": "https://clinicaltrials.gov/ct2/show/NCT05560139?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14", "source": null, "relevant": null }, { "trial_id": 391460, "title": "The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus", "summary": "<p>EudraCT Number: 2021-001144-98<br />Sponsor Protocol Number: LUB-COV-2021-01<br />Sponsor Name: Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie<br />Start Date: 2021-04-20<br />Medical condition: SARS-CoV-2 infection with one or more of the following symptoms: fever, cough, muscle aches, mild breathlessness, chest pain, diarrhea, nausea, vomiting, anosmia, lack of taste, sore throat, nasal ...<br />Disease: <br />Version: 23.1<br />SOC Term: 100000004848<br />Classification Code: 10084355<br />Term: COVID-19 virus test positive<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001144-98/PL\">PL</a> (Ongoing)</p>", "published_date": null, "discovery_date": "2022-09-29T06:05:13.299425Z", "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001144-98", "source": null, "relevant": null }, { "trial_id": 391452, "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav...", "summary": "<p>EudraCT Number: 2012-003176-39<br />Sponsor Protocol Number: 205MS303<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2013-05-31<br />Medical condition: Relapsing-remitting Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/DE\">DE</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/IT\">IT</a> (Prematurely Ended), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/CZ\">CZ</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/HU\">HU</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/PL\">PL</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/SE\">SE</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/ES\">ES</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/IE\">IE</a> (Prematurely Ended), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/GB\">GB</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/FI\">FI</a> (Prematurely Ended), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/GR\">GR</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/FR\">FR</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/DK\">DK</a> (Completed)</p>", "published_date": null, "discovery_date": "2022-09-29T06:05:13.287465Z", "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003176-39", "source": null, "relevant": null }, { "trial_id": 391003, "title": "Effect of the Vojta Therapy in Patients Multiple Sclerosis", "summary": "<b>Condition</b>: Multiple Sclerosis<br /><b>Intervention</b>: Other: Randomized clinical trial.<br /><b>Sponsors</b>: Aymara Abreu Corrales; University of Salamanca<br /><b>Not yet recruiting</b>", "published_date": "2022-09-28T12:00:00Z", "discovery_date": "2022-09-28T14:15:14.249469Z", "link": "https://clinicaltrials.gov/ct2/show/NCT05558683?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14", "source": null, "relevant": null }, { "trial_id": 388063, "title": "A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR...", "summary": "<p>EudraCT Number: 2019-003919-53<br />Sponsor Protocol Number: GN41791<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-12-17<br />Medical condition: Primary Progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GB\">GB</a> (GB - no longer in EU/EEA), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GR\">GR</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/AT\">AT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DE\">DE</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/PT\">PT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DK\">DK</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/HU\">HU</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/BG\">BG</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/IT\">IT</a> (Ongoing)</p>", "published_date": null, "discovery_date": "2022-09-23T12:25:18.584554Z", "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003919-53", "source": null, "relevant": null }, { "trial_id": 385651, "title": "EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis", "summary": "<b>Condition</b>: Cognitive Change<br /><b>Intervention</b>: Behavioral: EMRESERVA<br /><b>Sponsor</b>: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla<br /><b>Recruiting</b>", "published_date": "2022-09-19T12:00:00Z", "discovery_date": "2022-09-19T13:30:17.667371Z", "link": "https://clinicaltrials.gov/ct2/show/NCT05546424?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14", "source": null, "relevant": null }, { "trial_id": 384566, "title": "Real World Study to Evaluate Patient and Care Partner Ratings on Early Experience of Injection and Device for KESIMPTA® (Ofatumumab) Indicated for Multiple Sclerosis", "summary": null, "published_date": null, "discovery_date": "2022-09-17T16:52:59.582237Z", "link": "https://www.novartis.com//clinicaltrials/study/nct05334472", "source": "Novartis", "relevant": null }, { "trial_id": 384166, "title": "A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes(PRO) in patients with relapsing multiple sclerosis (RMS) transi...", "summary": "<p>EudraCT Number: 2019-001341-40<br />Sponsor Protocol Number: COMB157G23101<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2020-05-07<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/CZ\">CZ</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/DE\">DE</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/GR\">GR</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/HU\">HU</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SK\">SK</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BE\">BE</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PT\">PT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BG\">BG</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/ES\">ES</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/AT\">AT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PL\">PL</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/IT\">IT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SI\">SI</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/LV\">LV</a> (Ongoing)</p>", "published_date": null, "discovery_date": "2022-09-17T00:10:14.971105Z", "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001341-40", "source": null, "relevant": null }, { "trial_id": 383892, "title": "In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases", "summary": "<b>Conditions</b>: Autoimmune Diseases; Inflammatory Disease; Acquired Bone Marrow Aplasia; Systemic Lupus Erythematosus; Multiple Sclerosis; Gvhd; Rheumatoid Arthritis; Autoimmune Thyroiditis; Vitiligo; Alopecia; Atopic Dermatitis<br /><b>Intervention</b>: Other: Blood sample taken at a single time point<br /><b>Sponsor</b>: Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>", "published_date": "2022-09-16T12:00:00Z", "discovery_date": "2022-09-16T14:10:13.594162Z", "link": "https://clinicaltrials.gov/ct2/show/NCT05544448?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14", "source": null, "relevant": null }, { "trial_id": 383890, "title": "Cognitive Markers in Prodromal MS", "summary": "<b>Condition</b>: Multiple Sclerosis<br /><b>Intervention</b>: Device: Active tDCS<br /><b>Sponsors</b>: NYU Langone Health; National Multiple Sclerosis Society<br /><b>Recruiting</b>", "published_date": "2022-09-16T12:00:00Z", "discovery_date": "2022-09-16T14:10:13.588187Z", "link": "https://clinicaltrials.gov/ct2/show/NCT05543915?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14", "source": null, "relevant": null } ] }